Mwanzo38I • FRA
add
Intellia Therapeutics Inc
Bei iliyotangulia
€ 23.64
Bei za siku
€ 23.46 - € 23.95
Bei za mwaka
€ 18.46 - € 41.84
Thamani ya kampuni katika soko
2.51B USD
Wastani wa hisa zilizouzwa
75.00
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Mac 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 28.94M | 129.53% |
Matumizi ya uendeshaji wa biashara | 31.09M | 13.27% |
Mapato halisi | -107.44M | -4.18% |
Kiwango cha faida halisi | -371.30 | 54.61% |
Mapato kwa kila hisa | -1.12 | 4.27% |
EBITDA | -111.49M | -1.44% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Mac 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 791.29M | -15.24% |
Jumla ya mali | 1.26B | -11.16% |
Jumla ya dhima | 223.45M | -1.58% |
Jumla ya hisa | 1.04B | — |
hisa zilizosalia | 96.48M | — |
Uwiano wa bei na thamani | 2.20 | — |
Faida inayotokana na mali | -22.26% | — |
Faida inayotokana mtaji | -24.65% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Mac 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -107.44M | -4.18% |
Pesa kutokana na shughuli | -120.66M | -10.37% |
Pesa kutokana na uwekezaji | 5.90M | 104.83% |
Pesa kutokana na ufadhili | 59.99M | 2,601.13% |
Mabadiliko halisi ya pesa taslimu | -54.77M | 76.12% |
Mtiririko huru wa pesa | -61.17M | 16.51% |
Kuhusu
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2014
Makao Makuu
Tovuti
Wafanyakazi
526
